Movement Alert｜REMEGEN Falls 5.01% in Regular Trading, Earnings Window Nears Amid Biotechnology Sector Pressure

Market Focus10-22

On October 22, REMEGEN fell 5.01% in Regular Trading, trading at HK$63.5, with turnover of HK$56.78 million.

The most recent disclosed catalyst is that the company plans to review and approve its unaudited results for the nine months ended September 30 on October 29, placing the stock in a pre-earnings waiting period as the biotechnology sector also comes under pressure.

Sector sentiment was weak on the day, with AKESO falling 8.41%, INNOVENT BIO falling 6.23%, BEONE MEDICINES falling 2.33%, 3SBIO falling 3.5%, while MICOT PHARMA-B rose 14.89%. Earlier disclosures showed REMEGEN had also been active in liquidity management, including using RMB370 million of idle funds to buy wealth-management products in mid-October.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment